LifeMD (NASDAQ:LFMD) Earns Overweight Rating from Cantor Fitzgerald

LifeMD (NASDAQ:LFMD)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $15.00 target price on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 205.50% from the stock’s current price.

A number of other equities research analysts have also recently commented on LFMD. B. Riley initiated coverage on shares of LifeMD in a research report on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price for the company. KeyCorp lowered their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, LifeMD presently has a consensus rating of “Buy” and an average target price of $12.00.

LifeMD Stock Down 7.0 %

LFMD stock opened at $4.91 on Friday. The firm’s fifty day moving average is $5.70 and its 200 day moving average is $7.82. The firm has a market cap of $205.03 million, a PE ratio of -6.64 and a beta of 1.19. LifeMD has a one year low of $4.05 and a one year high of $12.88. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.83 and a current ratio of 0.87.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million for the quarter, compared to analyst estimates of $48.47 million. During the same quarter last year, the business posted ($0.23) EPS. On average, research analysts forecast that LifeMD will post -0.49 EPS for the current year.

Institutional Investors Weigh In On LifeMD

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of LifeMD during the 2nd quarter worth $31,000. EntryPoint Capital LLC acquired a new stake in shares of LifeMD during the first quarter valued at about $89,000. Los Angeles Capital Management LLC acquired a new stake in shares of LifeMD during the second quarter valued at about $88,000. The Manufacturers Life Insurance Company purchased a new stake in shares of LifeMD in the 2nd quarter valued at approximately $93,000. Finally, XTX Topco Ltd acquired a new position in shares of LifeMD in the 2nd quarter worth approximately $94,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.